FDAnews
www.fdanews.com/articles/90589-pharmion-s-vidaza-approved-for-iv-administration

PHARMION'S VIDAZA APPROVED FOR IV ADMINISTRATION

January 30, 2007

Pharmion has received approval from the FDA for its new drug application supplement to add intravenous (IV) use as a new route of administration to the approved prescribing information for its DNA demethylating agent Vidaza (azacitidine for injection). With this approval, Vidaza may now be administered intravenously over a period of 10 to 40 minutes in a clinic or hospital setting.

With IV administration, the dosing for Vidaza remains the same as the previously approved subcutaneous administration at 75 mg/m2 daily, for seven days, every four weeks. Pharmion will begin promoting this IV route of administration immediately.

The approval was based on existing clinical data from the original application, an uncontrolled Phase II study and a bioavailability study, as well as additional data from an in-use stability and compatibility study and a pharmacokinetic modeling study recently completed by Pharmion.

In 2004 Vidaza became the first drug approved by the FDA for the treatment of patients with myelodysplastic syndromes (MDS). The FDA approved Vidaza, the first in a class of drugs called demethylation agents, for treatment of all five MDS subtypes, which include: refractory anemia; refractory anemia with ringed sideroblasts if accompanied by neutropenia or thrombocytopenia or requiring transfusions; refractory anemia with excess blasts; refractory anemia with excess blasts in transformation; and chronic myelomonocytic leukemia.